Waltermire Robert E.
Known title: Senior VP, Chief Pharma Dev.CIK: 0001876996
Associated companies
Transaction History
| MDGL | ▲ Buy | Option Exercise | 7,288 | $635K | 3/5/2025 | View on chart |
| MDGL | ▼ Sell | Open Market | 900 | $302K | 3/5/2025 | View on chart |
| MDGL | ▲ Buy | Option Exercise | 6,825 | $600K | 3/5/2025 | View on chart |
| MDGL | ▼ Sell | Open Market | 1,777 | $598K | 3/5/2025 | View on chart |
| MDGL | ▼ Sell | Open Market | 1,043 | $357K | 3/5/2025 | View on chart |
| MDGL | ▼ Sell | Open Market | 1,077 | $369K | 3/5/2025 | View on chart |
| MDGL | ▼ Sell | Open Market | 4,701 | $1.6M | 3/5/2025 | View on chart |
| MDGL | ▼ Sell | Open Market | 1,412 | $487K | 3/5/2025 | View on chart |
| MDGL | ▲ Buy | Grant | 2,061 | $0 | 3/5/2025 | View on chart |
| MDGL | ▼ Sell | Open Market | 1,146 | $387K | 3/5/2025 | View on chart |
| MDGL | ▼ Sell | Open Market | 400 | $136K | 3/5/2025 | View on chart |
| MDGL | ▼ Sell | Open Market | 1,657 | $565K | 3/5/2025 | View on chart |
| MDGL | ▼ Sell | Open Market | 1,052 | $359K | 2/28/2025 | View on chart |
| MDGL | ▼ Sell | Open Market | 175 | $60K | 2/28/2025 | View on chart |
| MDGL | ▼ Sell | Open Market | 103 | $35K | 1/24/2025 | View on chart |
| MDGL | ▼ Sell | Open Market | 442 | $121K | 1/17/2025 | View on chart |
| MDGL | ▼ Sell | Open Market | 1,900 | $532K | 6/14/2024 | View on chart |
| MDGL | ▲ Buy | Option Exercise | 1,900 | $165K | 6/14/2024 | View on chart |
| MDGL | ▼ Sell | Open Market | 2,000 | $570K | 6/12/2024 | View on chart |
| MDGL | ▲ Buy | Option Exercise | 2,000 | $176K | 6/12/2024 | View on chart |
| MDGL | ▼ Sell | Open Market | 1,036 | $240K | 5/21/2024 | View on chart |
| MDGL | ▲ Buy | Grant | 1,419 | $0 | 1/23/2024 | View on chart |
| MDGL | ▼ Sell | Tax Withholding | 550 | $134K | 1/16/2024 | View on chart |
| MDGL | ▲ Buy | Option Exercise | 2,000 | $176K | 12/15/2023 | View on chart |
| MDGL | ▼ Sell | Open Market | 1,000 | $236K | 12/15/2023 | View on chart |
| MDGL | ▼ Sell | Open Market | 1,000 | $241K | 12/15/2023 | View on chart |
| MDGL | ▲ Buy | Option Exercise | 2,000 | $176K | 12/14/2023 | View on chart |
| MDGL | ▼ Sell | Open Market | 1,000 | $232K | 12/14/2023 | View on chart |
| MDGL | ▼ Sell | Open Market | 1,000 | $233K | 12/14/2023 | View on chart |
| MDGL | ▲ Buy | Option Exercise | 2,500 | $220K | 12/13/2023 | View on chart |
| MDGL | ▼ Sell | Open Market | 1,000 | $226K | 12/13/2023 | View on chart |
| MDGL | ▼ Sell | Open Market | 1,500 | $338K | 12/13/2023 | View on chart |
| MDGL | ▼ Sell | Open Market | 500 | $108K | 12/12/2023 | View on chart |
| MDGL | ▼ Sell | Open Market | 800 | $175K | 12/12/2023 | View on chart |
| MDGL | ▲ Buy | Option Exercise | 1,300 | $114K | 12/12/2023 | View on chart |
| MDGL | ▲ Buy | Option Exercise | 5,000 | $440K | 3/1/2023 | View on chart |
| MDGL | ▼ Sell | Open Market | 1,928 | $527K | 3/1/2023 | View on chart |
| MDGL | ▼ Sell | Open Market | 1,672 | $459K | 3/1/2023 | View on chart |
| MDGL | ▼ Sell | Open Market | 1,300 | $358K | 3/1/2023 | View on chart |
| MDGL | ▼ Sell | Open Market | 100 | $28K | 3/1/2023 | View on chart |
| MDGL | ▲ Buy | Option Exercise | 5,000 | $440K | 2/28/2023 | View on chart |
| MDGL | ▼ Sell | Open Market | 900 | $244K | 2/28/2023 | View on chart |
| MDGL | ▼ Sell | Open Market | 4,100 | $1.1M | 2/28/2023 | View on chart |
| MDGL | ▲ Buy | Grant | 5,667 | $0 | 1/16/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Madrigal Publishes MAESTRO-NASH Secondary Analysis Data
Madrigal Pharmaceuticals has published data from a pre-specified secondary analysis of its Phase 3 MAESTRO-NASH study in the Journal of Hepatology. The analysis evaluates how patients with altered MASH profiles respond to Rezdiffra. This update provides additional clinical context for the drug's performance in specific patient groups.
Madrigal Publishes MAESTRO-NASH Secondary Analysis Data. Madrigal Pharmaceuticals has published data from a pre-specified secondary analysis of its Phase 3 MAESTRO-NASH study in the Journal of Hepatology. The analysis evaluates how patients with altered MASH profiles respond to Rezdiffra. This update provides additional clinical context for the drug's performance in specific patient groups.